ANRO — Alto Neuroscience, Inc.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1999480 ·
Last close
$26.48
Market Cap
$929.29M
52W High
$28.44
52W Low
$17.90
ADV30
553,041
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -27,138,000 | -26,237,000 | 276,259,000 | 263,762,000 | 32,890,000 |
| Dec 2025 | 0 | — | -17,055,000 | -16,182,000 | 184,689,000 | 176,484,000 | 33,547,000 |
| Sep 2025 | 0 | — | -14,951,000 | -14,181,000 | 147,006,000 | 137,816,000 | 35,449,000 |
| Jun 2025 | 0 | — | -18,682,000 | -17,706,000 | 157,877,000 | 147,585,000 | 34,465,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-62,304,000
Investing CF
$-556,000
Financing CF
$165,892,000
CapEx
$-2,091,000
Dividends Paid
—
Buybacks
$-4,775,000
EPS Diluted TTM
$-2.53
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-227,871,000
Inventory
—
Receivables
$0
ST Investments
—
EBIT TTM
$-71,890,000
Pretax Income TTM
$-74,306,000
Interest Exp TTM
$2,416,000
Analysts
11
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -66,364,000 | -63,238,000 | 184,689,000 | 33,547,000 | — | -51,769,000 |
| Dec 2024 | 0 | -68,610,000 | -61,431,000 | 177,542,000 | 26,082,000 | — | -47,424,000 |
| Dec 2023 | 0 | -37,809,000 | -36,305,000 | 86,628,000 | 158,300,000 | — | -33,448,000 |
| Dec 2022 | 0 | -27,455,000 | -27,710,000 | 50,854,000 | 89,260,000 | — | -20,394,000 |
TTM Snapshot
Revenues TTM
$3,214,000
NetIncome TTM
$-25,924,000
OpCashFlow TTM
$0
Assets (Latest)
$177,542,000
Forward EPS
$-3.43
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LBRX | LB PHARMACEUTICALS INC | $944.90M | $32.95 | — |
| ABUS | Arbutus Biopharma Corp | $948.18M | $4.80 | — |
| DSGN | Design Therapeutics, Inc. | $948.72M | $15.19 | — |
| ANNX | Annexon, Inc. | $950.29M | $5.80 | — |
| FBRX | Forte Biosciences, Inc. | $899.43M | $43.92 | — |
News headlines (Yahoo Finance, 1h cache)
Is Alto Neuroscience, Inc. (ANRO) Stock Positioned for Growth With New Insights Into Anhedonia Treatment?
2026-07-02 19:58 · Yahoo
Alto Neuroscience Highlights Nature Medicine Publication Demonstrating Significant Effects of Pramipexole on Anhedonia
2026-06-15 12:03 · Yahoo
Alpha Wave Global Initiates COPT Defense Properties Position, According to Recent SEC Filing
2026-05-27 05:19 · Yahoo
Top 1% Alto Neuroscience Plummets On Its Shocking Schizophrenia Miss
2026-04-02 20:10 · Yahoo
Sector Update: Health Care Stocks Softer Late Afternoon
2026-04-02 19:57 · Yahoo
Update: Alto Neuroscience Shares Fall After Phase 2 Trial of ALTO-101 Yields Statistically Insignificant Data
2026-04-02 18:36 · Yahoo
Immunovant eye drug flunks Phase 3 studies; Beam sickle cell data published in NEJM
2026-04-02 12:20 · Yahoo
Alto Neuroscience CFO Nick Smith on Firm’s $120 Million Private Placement
2026-03-23 15:14 · Yahoo
NYSE Content Update: Alto Neuroscience Raises $120 Million to Fund Development of ALTO-207
2026-03-23 12:55 · Yahoo
Bipolar Depression Market Expected to Witness Accelerated Expansion During the Forecast Period (2026-2036) Amid Advancements in Psychiatric Therapies | DelveInsight
2026-03-11 21:31 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.